Curetis' Unyvero Intra-Abdominal Infection (IAI) Cartridge Receives CE Marking
Product to launch in EMEA at ECCMID Conference April 22-25, 2017 / IAI Panel covers up to 130 diagnostic targets
The prospective, multi-center study to evaluate clinical performance was conducted over the past few months at major hospitals in the UK, in France, and Italy. In total, 332 patient samples were tested and 679 pathogens were determined as true positives using the Unyvero IAI Application Cartridge. Overall weighted average sensitivity for the pathogens specifically targeted by the test panel was 93.8% at an overall weighted average specificity of 99.7% following discrepant result resolution.
A particular strength of the IAI cartridge is the reliable detection of anaerobic bacteria that are notoriously hard to cultivate and thus often missed by routine microbiological culture. Further, the Unyvero IAI has also demonstrated the ability to deliver results on pathogens, toxins, and resistance markers much faster than microbiology culture, the current standard of care.
The IAI Cartridge aims to support clinicians in the fast and reliable diagnosis of various severe conditions, including peritonitis, cholecystitis and acute pancreatitis, and addresses a market of up to 1.9 million patients in hospitalized settings in Europe and the U.S. per year. Together with the Unyvero System, the IAI Cartridge can process a broad variety of clinical samples including tissue, ascites in positively flagged blood cultures, and gastric juice.
Complicated intra-abdominal infections are a common problem. In Germany alone, there are about 150,000 cases of severe intra-abdominal infections per year. In the U.S., appendicitis alone affects about 300,000 patients per year and is responsible for more than 1 million hospital days. Every fourth case of severe sepsis or septic shock can be attributed to intra-abdominal infections, and various independent studies show an overall mortality rate of 7.5%.
"We are excited about this fourth unique application now being launched for our Unyvero System," said Dr. Achim Plum, CCO of Curetis. "The IAI Cartridge complements our Pneumonia, ITI and BCU cartridges, and further expands our portfolio of applications for severe infections in hospitalized patients. It will not only allow existing Unyvero customers to further broaden the use of their systems, but it will also attract new customer groups."
Dr. Oliver Schacht, CEO of Curetis, added, "The IAI panel is a first in class and highly differentiated syndromic testing panel and will be followed by new panels in the areas of severe urinary tract infections, sepsis host response, expanded panels in respiratory diseases and cardiology-related infections in the coming years."
CAUTION - Investigational device. Limited by Federal (or United States) law to investigational use. The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on the Curetis Unyvero technology is currently available for sale in the United States of America or Canada. The analytical and clinical performance characteristics of any Curetis Unyvero product which may be sold at some future point in time in the U.S. have not yet been established.
This document constitutes neither an offer to buy nor to subscribe securities and neither this document nor any part of it should form the basis of any investment decision in Curetis.
The information contained in this press release has been carefully prepared. However, Curetis bears and assumes no liability of whatever kind for the correctness and completeness of the information provided herein. Curetis does not assume an obligation of whatever kind to update or correct information contained in this press release whether as a result of new information, future events or for other reasons.
This press release includes statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements Curetis makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. Curetis' actual results may differ materially from those predicted by the forward-looking statements. Curetis undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.
Founded in 2007, Curetis is a molecular diagnostics company which focuses on the development and commercialization of reliable, fast and cost-effective products for diagnosing severe infectious diseases. The diagnostic solutions of Curetis enable rapid multi-parameter pathogen and antibiotic resistance marker detection in only a few hours, a process that today can take up to days or even weeks with other techniques.
To date, Curetis has raised EUR 44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels and private equity funds of over EUR 63.5 million. Furthermore, Curetis has entered into a debt financing facility with EIB for up to EUR 25 million. The company is based in Holzgerlingen near Stuttgart, Germany. Curetis collaborates with Heraeus Medical, pharmaceutical companies, and has entered into several international distribution agreements covering many countries across Europe, the Middle East and Asia.
In 2017, Curetis established Ares Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna, Austria. Ares Genetics is dedicated to maximizing the R&D and related scientific and business opportunities of the GEAR assets acquired in 2016 for the entire Curetis Group.
For further information, please visit www.curetis.com.
Press releases you might also be interested in
Weitere Informationen zum Thema "Forschung und Entwicklung":
Diese Vorteile bietet Machine Learning mit Apache Kafka
Machine Learning sowie das zugehörige Deep Learning nehmen Fahrt auf, da Machine Learning es Computern ermöglicht, versteckte Erkenntnisse zu gewinnen, ohne dass diese explizit programmiert sein müssen, worauf sie schauen sollen. Diese Fähigkeit wird für die Analyse unstrukturierter Daten, Bilderkennung, Spracherkennung und intelligente Entscheidungsfindung benötigt. Das macht einen großen Unterschied zur traditionellen Programmierung mit Java, .NET oder Python.Weiterlesen